Document is current
Any future updates will be listed below
-
Authors
Zhang, Xin https://orcid.org/0009-0001-2383-3115
Cheng, Hong Sheng https://orcid.org/0000-0001-9745-7872
Zhan, Xueliang
Li, Xue
Huang, Jiamin
Liu, Haoyu https://orcid.org/0009-0000-6280-9962
Chua, Damien https://orcid.org/0000-0003-0007-1688
Wang, Guoze
Li, Xingxing
Shi, Yue
Wang, Fuxiang
Xu, Zhe
Qu, Jiuxin
Pethe, Kevin https://orcid.org/0000-0003-0916-8873
Li, Guobao
Tan, Nguan Soon https://orcid.org/0000-0003-0136-7341
Mac Aogáin, Micheál https://orcid.org/0000-0002-1726-7700
Chotirmall, Sanjay H. https://orcid.org/0000-0003-0417-7607
Li, Liang https://orcid.org/0000-0003-1001-7837
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 8 January 2026
First Online: 27 March 2026
Competing interests
: S.H.C. is on advisory boards for CSL Behring, Pneumagen, Sanofi and Boehringer Ingelheim, serves on Data and Safety Monitoring Boards for Inovio Pharmaceuticals and Imam Abdulrahman Bin Faisal University, and has received personal fees from Chesi Farmaceutici and Astra-Zeneca, all outside of the submitted work. All other authors declare no competing interests.
